Physician profile
John A Floreno
NPI 1104800481
$2,575.72
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $820 · 2020: $91.99 · 2021: $274 · 2022: $328 · 2023: $607 · 2024: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,061.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $830.52 | 2019-2024 | Wegovy |
| Glaxosmithkline, LLC. | $368.92 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $212.58 | 2019-2024 | Airsupra, Breztri |
| Pfizer INC. | $180.75 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.82 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $101.62 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Novartis Pharmaceuticals Corporation | $97.67 | 2019 | |
| Amgen INC. | $93.72 | 2019-2024 | Repatha, Otezla |
| Mylan Specialty L.P. | $91.30 | 2023-2024 | Yupelri |
| Exact Sciences Corporation | $88.22 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $77.97 | 2019 | |
| Abbvie INC. | $63.72 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $28.84 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $24.59 | 2022-2023 | Seglentis, Livalo |
| Abbott Laboratories | $23.39 | 2023 | Freestyle Libre 3 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $22.34 | 2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $19.49 | 2023 | |
| Sunovion Pharmaceuticals INC. | $17.81 | 2019 | |
| Horizon Therapeutics Plc | $16.48 | 2023 | Krystexxa |
| Nestle Healthcare Nutrition INC. | $15.09 | 2023 | |
| Sanofi-Aventis U.S. LLC | $15.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.39 | 2019 | |
| Ibsa Pharma INC. | $13.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Floreno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.